IL319266A - RAD1901 for use in cancer treatment - Google Patents

RAD1901 for use in cancer treatment

Info

Publication number
IL319266A
IL319266A IL319266A IL31926625A IL319266A IL 319266 A IL319266 A IL 319266A IL 319266 A IL319266 A IL 319266A IL 31926625 A IL31926625 A IL 31926625A IL 319266 A IL319266 A IL 319266A
Authority
IL
Israel
Prior art keywords
rad1901
tumor
treatment
fulvestrant
dose
Prior art date
Application number
IL319266A
Other languages
English (en)
Hebrew (he)
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of IL319266A publication Critical patent/IL319266A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL319266A 2015-04-29 2016-04-29 RAD1901 for use in cancer treatment IL319266A (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201562154699P 2015-04-29 2015-04-29
US201562155451P 2015-04-30 2015-04-30
US201562158469P 2015-05-07 2015-05-07
US201562192940P 2015-07-15 2015-07-15
US201562192944P 2015-07-15 2015-07-15
US201562252085P 2015-11-06 2015-11-06
US201562252916P 2015-11-09 2015-11-09
US201562265696P 2015-12-10 2015-12-10
US201562265658P 2015-12-10 2015-12-10
US201562265774P 2015-12-10 2015-12-10
US201562265663P 2015-12-10 2015-12-10
US201662323576P 2016-04-15 2016-04-15
US201662323572P 2016-04-15 2016-04-15
PCT/US2016/030317 WO2016176665A1 (en) 2015-04-29 2016-04-29 Methods of treating cancer

Publications (1)

Publication Number Publication Date
IL319266A true IL319266A (en) 2025-04-01

Family

ID=57198783

Family Applications (10)

Application Number Title Priority Date Filing Date
IL319266A IL319266A (en) 2015-04-29 2016-04-29 RAD1901 for use in cancer treatment
IL255148A IL255148B2 (en) 2015-04-29 2016-04-29 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
IL310069A IL310069B2 (en) 2015-04-29 2016-04-29 Rad1901 for use in the treatment of cancer
IL297369A IL297369B2 (en) 2015-04-29 2016-04-29 RAD for use in a method to treat mutant estrogen receptor-positive breast cancer or mutant estrogen receptor-positive ovarian cancer
IL255189A IL255189B2 (en) 2015-04-29 2016-04-29 A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
IL255261A IL255261B2 (en) 2015-04-29 2016-04-29 A combination of an m-tor inhibitor and rad19010 for use in a method of inhibiting tumor growth or producing tumor regression in a subject having a deug-resistant andqor mutant estrogen receptor
IL307981A IL307981B1 (en) 2015-04-29 2023-10-24 Combination of everolimus and rad1901 for use in inhibiting tumor growth or inducing tumor regression
IL307983A IL307983B1 (en) 2015-04-29 2023-10-24 Combination of palbociliv and rad1901 for use in inhibiting tumor growth or inducing tumor regression
IL323926A IL323926A (en) 2015-04-29 2025-10-13 Combination of palbociclib and rad1901 for use in inhibiting tumor growth or inducing tumor regression
IL323924A IL323924A (en) 2015-04-29 2025-10-13 Combination of everolimus and rad1901 for use in inhibiting tumor growth or inducing tumor regression

Family Applications After (9)

Application Number Title Priority Date Filing Date
IL255148A IL255148B2 (en) 2015-04-29 2016-04-29 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
IL310069A IL310069B2 (en) 2015-04-29 2016-04-29 Rad1901 for use in the treatment of cancer
IL297369A IL297369B2 (en) 2015-04-29 2016-04-29 RAD for use in a method to treat mutant estrogen receptor-positive breast cancer or mutant estrogen receptor-positive ovarian cancer
IL255189A IL255189B2 (en) 2015-04-29 2016-04-29 A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
IL255261A IL255261B2 (en) 2015-04-29 2016-04-29 A combination of an m-tor inhibitor and rad19010 for use in a method of inhibiting tumor growth or producing tumor regression in a subject having a deug-resistant andqor mutant estrogen receptor
IL307981A IL307981B1 (en) 2015-04-29 2023-10-24 Combination of everolimus and rad1901 for use in inhibiting tumor growth or inducing tumor regression
IL307983A IL307983B1 (en) 2015-04-29 2023-10-24 Combination of palbociliv and rad1901 for use in inhibiting tumor growth or inducing tumor regression
IL323926A IL323926A (en) 2015-04-29 2025-10-13 Combination of palbociclib and rad1901 for use in inhibiting tumor growth or inducing tumor regression
IL323924A IL323924A (en) 2015-04-29 2025-10-13 Combination of everolimus and rad1901 for use in inhibiting tumor growth or inducing tumor regression

Country Status (14)

Country Link
US (12) US20180214393A1 (enExample)
EP (4) EP3288383A4 (enExample)
JP (9) JP6926066B2 (enExample)
KR (9) KR102682763B1 (enExample)
CN (5) CN108135177B (enExample)
AU (3) AU2016256469B2 (enExample)
BR (3) BR112017023228A2 (enExample)
CA (3) CA2984195C (enExample)
HK (3) HK1251407A1 (enExample)
IL (10) IL319266A (enExample)
MX (6) MX384908B (enExample)
RU (3) RU2745678C2 (enExample)
SG (4) SG11201708861VA (enExample)
WO (3) WO2016176666A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3288383A4 (en) * 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
PE20181893A1 (es) 2016-02-15 2018-12-11 Sanofi Sa Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
SG11201901759XA (en) * 2016-09-27 2019-04-29 Radius Health Inc Methods for treating ovarian cancer
BR112019007254A2 (pt) 2016-10-11 2019-07-02 Duke University tratamento lasofoxifeno de câncer de mama er+
JP6946430B2 (ja) 2016-11-17 2021-10-06 サノフイＳａｎｏｆｉ 新規の置換ｎ−（３−フルオロプロピル）−ピロリジン化合物、それを製造するための方法、およびその治療的使用
ES2981967T3 (es) * 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
CN110636862A (zh) * 2017-03-16 2019-12-31 卫材 R&D 管理有限公司 用于治疗乳腺癌的组合疗法
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP2021503448A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー Ｌｓｚ１０２及びリボシクリブを含む医薬組合せ
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US10695333B2 (en) 2017-12-01 2020-06-30 Novartis Ag Pharmaceutical combination comprising LSZ102 and alpelisib
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN110585429B (zh) * 2018-06-12 2022-10-21 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途
JP7473486B2 (ja) * 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
AU2019335542A1 (en) 2018-09-07 2021-04-01 Sanofi Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-(4-((3s)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxyphenyl)-8,9-dihydro-7H-benzo(7)annulene-2-carboxylate
MY209833A (en) * 2018-11-30 2025-08-07 Radius Pharmaceuticals Inc Elacestrant in combination with abemaciclib in women with breast cancer
EA202191283A1 (ru) * 2018-12-06 2021-10-13 Радиус Фармасьютикалс, Инк. Способы лечения устойчивого к ингибиторам cdk4/6 рака
JP7497353B2 (ja) * 2018-12-06 2024-06-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
IL283885B1 (en) * 2018-12-12 2025-10-01 Chemocentryx Inc CXCR7 inhibitors for cancer treatment
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
BR112021022216A2 (pt) * 2019-05-09 2021-12-28 Sanofi Sa Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
MX2022000279A (es) 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
IL297216A (en) * 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
JP2023500558A (ja) * 2020-05-12 2023-01-10 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５及びｃｄｋ４／６阻害剤を含む併用療法を使用した乳がん治療
MX2023001572A (es) * 2020-08-05 2023-05-08 Aizant Drug Res Solutions Private Limited Formas farmaceuticas sólidas de palbociclib.
CA3202592A1 (en) * 2020-12-14 2022-06-23 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
AU2022222660A1 (en) * 2021-02-16 2023-07-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
CN113662942B (zh) * 2021-08-19 2023-02-07 中国人民解放军陆军军医大学第一附属医院 药物组合物及其在smo突变性髓母细胞瘤中的应用
WO2023064519A1 (en) 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof
DE102021130035A1 (de) 2021-11-17 2023-05-17 USound GmbH MEMS-Schallwandler mit einer gekrümmten Kontur eines Kragarmelements
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2024104268A1 (zh) * 2022-11-15 2024-05-23 苏州科睿思制药有限公司 艾拉司群二盐酸盐的共晶及其制备方法和用途
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4574811A1 (en) 2023-12-22 2025-06-25 Sandoz Ag Crystalline forms of elacestrant dihydrochloride
WO2025158416A1 (en) 2024-01-25 2025-07-31 Assia Chemical Industries Ltd. Solid state forms of elacestrant and processes for preparation thereof

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
TR200000649T2 (tr) 1997-09-09 2000-09-21 F.Hoffmann-La Roche Ag PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
DE69806963T2 (de) 1997-12-11 2002-11-21 Alza Corp., Mountain View Vorrichtung zur erhöhung des transdermalen wirkstoffeflusses
WO1999029365A1 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20010044431A1 (en) 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
CA2420289A1 (en) 2000-08-23 2002-02-28 Akzo Nobel N.V. 10-aryl-11-hbenzo [b]fluorene derivatives and analogs for medicinal use
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
BR0114909A (pt) 2000-10-26 2004-02-03 Alza Corp Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas
ES2333849T3 (es) 2001-04-20 2010-03-02 Alza Corporation Disposicion de microsalientes que presenta un revestimiento que contiene un agente beneficioso.
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
US6881203B2 (en) 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
PT1465535E (pt) 2001-12-20 2008-02-08 Alza Corp Microprojecções que perfuram a pele tendo controlo de profundidade de perfuração
WO2003063859A1 (en) 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
WO2003068805A2 (en) 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
WO2003099849A2 (en) 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
WO2003105772A2 (en) 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
JP2006502116A (ja) 2002-07-12 2006-01-19 メダレックス， インク． タンパク質の酸化分解を防ぐ方法及び組成物
MXPA05000597A (es) 2002-07-19 2005-04-28 3M Innovative Properties Co Dispositivos de microaguja y aparatos de administracion por microaguja.
PL376223A1 (en) 2002-10-14 2005-12-27 Novo Nordisk As Glucagon - like peptide - 2 variants
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
AU2002359391A1 (en) 2002-11-01 2004-07-29 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
WO2004058682A1 (ja) * 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
US20060142387A1 (en) 2003-06-10 2006-06-29 Rodolfo Cadilla Chemical compounds
WO2005000795A2 (en) 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
MXPA06000281A (es) 2003-06-30 2006-07-03 Johnson & Johnson Formulaciones para microproyecciones revestidas que contienen contraiones no volatiles.
BRPI0412021A (pt) 2003-06-30 2006-08-15 Alza Corp método para revestir microprojeções de perfuração de pele
US20050032698A1 (en) 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
AU2004287059A1 (en) 2003-10-28 2005-05-19 Alza Corporation Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections
WO2005044333A2 (en) 2003-10-31 2005-05-19 Alza Corporation Self-actuating applicator for microprojection array
CN100548228C (zh) 2003-11-13 2009-10-14 阿尔扎公司 用于透皮递送的组合物和装置
BRPI0416208A (pt) 2003-11-20 2006-12-26 Warner Lambert Co moduladores de receptores de androgênio
JP2007518468A (ja) 2003-11-21 2007-07-12 アルザ・コーポレーシヨン 超音波支援経皮ワクチン送達方法およびシステム
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
KR101536701B1 (ko) 2004-01-07 2015-07-14 앙도르쉐르슈 인코포레이티드 헬릭스 12 배향형 스테로이드계 약학 제품
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
CA2562132A1 (en) 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
MXPA06012980A (es) 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
CA2565544A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
EP1765406A4 (en) 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
JP2008518968A (ja) 2004-10-29 2008-06-05 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド
CA2588080C (en) 2004-11-18 2013-01-08 3M Innovative Properties Company Masking method for coating a microneedle array
EP1848498A4 (en) 2004-11-18 2009-12-16 Transpharma Medical Ltd ASSOCIATED MICRO-CHANNEL PRODUCTION AND IONTOPHORESIS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
AU2006206272A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
JP2008536868A (ja) 2005-04-15 2008-09-11 スミスクライン・ビーチャム・コーポレイション シアノアリールアミン
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
AR057656A1 (es) 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
US20070021216A1 (en) 2005-07-19 2007-01-25 Sony Ericsson Mobile Communications Ab Seamless gaming method and apparatus
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
EP1948139A4 (en) 2005-11-18 2012-04-04 3M Innovative Properties Co COATING COMPOSITIONS, COATINGS DERIVED THEREFROM, AND MICRO-NETWORKS COMPRISING SUCH COATINGS
US8632801B2 (en) 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
JP2009530307A (ja) 2006-03-15 2009-08-27 アルザ コーポレイション 骨減少症を予防し、または治療するための副甲状腺ホルモン薬の経皮送達のための装置、並びに方法
WO2007124465A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
CN101472676B (zh) 2006-04-20 2013-09-11 万罗赛斯公司 利用微通道工艺技术处理和/或形成一种非牛顿流体的方法
WO2007124411A1 (en) 2006-04-20 2007-11-01 3M Innovative Properties Company Device for applying a microneedle array
CN101085743B (zh) 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
PT2054049E (pt) 2006-08-24 2016-06-02 Univ Tennessee Res Found Acilanilidas substituídas e métodos de utilização das mesmas
AR062522A1 (es) 2006-08-25 2008-11-12 Ares Trading Sa Tratamiento de desordenes en cartilagos
CN1927815A (zh) 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
JP5375611B2 (ja) 2006-10-03 2013-12-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
US20100030100A1 (en) 2007-02-06 2010-02-04 Hisamitsu Pharmaceutical Co., Inc. Microneedle Device For Diagnosis Of Allergy
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US9114238B2 (en) 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
WO2008145125A1 (en) * 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
US20110009387A1 (en) 2007-06-12 2011-01-13 Andrea Dawn Basso-Porcaro Histone h2ax (hh2ax) biomarker for fti sensitivity
WO2008157425A2 (en) 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
JP5559054B2 (ja) 2007-09-28 2014-07-23 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 送達装置および方法
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
WO2009065126A2 (en) 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
US20110124617A1 (en) * 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
US20100092566A1 (en) 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US8329649B2 (en) 2008-11-04 2012-12-11 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone and histidine
CN105999538A (zh) 2008-11-18 2016-10-12 3M创新有限公司 空心微针阵列和方法
JP5902390B2 (ja) 2008-12-26 2016-04-13 久光製薬株式会社 マイクロニードルデバイス
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
CA2759850C (en) 2009-04-24 2019-10-22 Corium International, Inc. Methods for manufacturing microprojection arrays
US10010706B2 (en) 2009-07-31 2018-07-03 3M Innovative Properties Company Hollow microneedle arrays
US20120219538A1 (en) 2009-11-02 2012-08-30 Therapeomic Ag Stabilized protein formulations and use thereof
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
CN101912600B (zh) 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
AU2011258288B2 (en) 2010-05-28 2015-02-12 Kindeva Drug Delivery L.P. Aqueous formulations for coating microneedle arrays
WO2011156908A1 (en) * 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
CA2829020A1 (en) 2011-03-01 2012-09-07 Sloan-Kettering Institute For Cancer Research Parathyroid hormone analogs, compositions and uses thereof
US20130006217A1 (en) 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
AU2012345768B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
GB201217439D0 (en) 2012-09-28 2012-11-14 Topotarget As Combination therapy
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN104436194B (zh) 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
WO2015113062A1 (en) * 2014-01-27 2015-07-30 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
PT3122426T (pt) * 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
US12263141B2 (en) 2025-04-01
NZ737822A (en) 2024-10-25
CA2984200C (en) 2024-03-19
JP7745708B2 (ja) 2025-09-29
AU2016256469A1 (en) 2017-12-14
RU2017140676A (ru) 2019-05-29
NZ737825A (en) 2024-10-25
IL297369B2 (en) 2024-06-01
IL323924A (en) 2025-12-01
JP7019422B2 (ja) 2022-02-15
RU2747228C2 (ru) 2021-04-29
MX2017013802A (es) 2018-08-15
IL255261A0 (en) 2017-12-31
AU2016256470A1 (en) 2017-12-14
CN108135177B (zh) 2021-06-01
IL307983A (en) 2023-12-01
JP6926065B2 (ja) 2021-08-25
RU2017140675A (ru) 2019-05-29
KR20180011780A (ko) 2018-02-02
IL255148B2 (en) 2023-04-01
AU2016256471A1 (en) 2017-12-21
EP3288382A4 (en) 2019-01-30
CA2984195C (en) 2023-10-24
SG11201708860SA (en) 2017-11-29
MX2021003389A (es) 2021-05-28
MX2017013801A (es) 2018-08-15
JP2018514549A (ja) 2018-06-07
KR102871380B1 (ko) 2025-10-14
KR20250153309A (ko) 2025-10-24
US20250367141A1 (en) 2025-12-04
JP2024120996A (ja) 2024-09-05
AU2016256469B2 (en) 2020-12-10
JP7696378B2 (ja) 2025-06-20
KR20180043202A (ko) 2018-04-27
IL307981B1 (en) 2025-11-01
RU2017140674A (ru) 2019-05-29
KR102676629B1 (ko) 2024-06-18
US11819480B2 (en) 2023-11-21
CN108024541A (zh) 2018-05-11
EP3288383A4 (en) 2019-01-23
KR20240110098A (ko) 2024-07-12
JP6926066B2 (ja) 2021-08-25
HK1251409A1 (zh) 2019-02-01
KR20180042155A (ko) 2018-04-25
IL310069B1 (en) 2025-04-01
MX2017013794A (es) 2018-08-15
CN113750091B (zh) 2025-03-11
US20180214393A1 (en) 2018-08-02
SG11201708861VA (en) 2017-11-29
IL307983B1 (en) 2025-11-01
JP2023052631A (ja) 2023-04-11
RU2017140674A3 (enExample) 2019-09-27
IL323926A (en) 2025-12-01
BR112017023269A2 (en) 2018-11-06
AU2016256470B2 (en) 2020-10-15
IL297369B1 (en) 2024-02-01
RU2017140676A3 (enExample) 2019-09-27
JP2021102640A (ja) 2021-07-15
NZ737819A (en) 2024-10-25
US20250367140A1 (en) 2025-12-04
EP3288382A1 (en) 2018-03-07
EP4039253A1 (en) 2022-08-10
WO2016176664A1 (en) 2016-11-03
IL255148B (en) 2022-12-01
JP2025170141A (ja) 2025-11-14
JP2021105064A (ja) 2021-07-26
HK1251407A1 (zh) 2019-02-01
IL255261B1 (en) 2023-11-01
IL307981A (en) 2023-12-01
RU2737496C2 (ru) 2020-12-01
BR112017023233A2 (en) 2018-11-06
CN108024541B (zh) 2021-07-20
IL255189B2 (en) 2024-04-01
US20240091177A1 (en) 2024-03-21
HK1251408A1 (zh) 2019-02-01
AU2016256469A8 (en) 2017-12-21
CN108135177A (zh) 2018-06-08
JP7516472B2 (ja) 2024-07-16
MX393599B (es) 2025-03-19
KR102676705B1 (ko) 2024-06-18
EP3294065A1 (en) 2018-03-21
IL310069A (en) 2024-03-01
SG10202104177VA (en) 2021-05-28
MX2021004881A (es) 2021-07-21
JP7262508B2 (ja) 2023-04-21
MX384908B (es) 2025-03-14
AU2016256471B2 (en) 2020-09-10
MX384605B (es) 2025-03-14
US11413258B2 (en) 2022-08-16
EP3288383A1 (en) 2018-03-07
US20200046655A1 (en) 2020-02-13
KR20250152678A (ko) 2025-10-23
WO2016176665A1 (en) 2016-11-03
CN108024540B (zh) 2021-09-17
CA2984200A1 (en) 2016-11-03
CA2984357A1 (en) 2016-11-03
JP2022172039A (ja) 2022-11-14
US20180153828A1 (en) 2018-06-07
RU2745678C2 (ru) 2021-03-30
US20240099996A1 (en) 2024-03-28
JP7146992B2 (ja) 2022-10-04
US20220110890A1 (en) 2022-04-14
IL255189A0 (en) 2017-12-31
US20200038343A1 (en) 2020-02-06
CA2984195A1 (en) 2016-11-03
WO2016176666A1 (en) 2016-11-03
RU2017140675A3 (enExample) 2019-09-27
KR20250152679A (ko) 2025-10-23
IL255189B1 (en) 2023-12-01
US20220339126A1 (en) 2022-10-27
KR102871388B1 (ko) 2025-10-14
MX2021005561A (es) 2022-07-01
US20180169101A1 (en) 2018-06-21
IL255148A0 (en) 2017-12-31
EP3294065A4 (en) 2019-03-20
KR102682763B1 (ko) 2024-07-05
KR20240097966A (ko) 2024-06-27
MX394676B (es) 2025-03-24
BR112017023228A2 (en) 2018-11-06
CN108024540A (zh) 2018-05-11
SG11201708858WA (en) 2017-11-29
IL255261B2 (en) 2024-03-01
IL310069B2 (en) 2025-08-01
IL297369A (en) 2022-12-01
KR20240095372A (ko) 2024-06-25
JP2018514593A (ja) 2018-06-07
CN113750091A (zh) 2021-12-07
CN113288887A (zh) 2021-08-24
US20200368183A1 (en) 2020-11-26
KR102871408B1 (ko) 2025-10-14
JP2018518529A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
US20240099996A1 (en) Methods for treating cancer
HK40079056A (en) Methods of treating cancer